The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/6/598 |
| _version_ | 1797531395383361536 |
|---|---|
| author | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Mansoor Ashraf Michael F. Drummond Milton C. Weinstein |
| author_facet | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Mansoor Ashraf Michael F. Drummond Milton C. Weinstein |
| author_sort | Michele A. Kohli |
| collection | DOAJ |
| description | Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves. Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94. Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (−682,000), hospitalizations (−5800) and deaths (−740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving. Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons. |
| first_indexed | 2024-03-10T10:43:11Z |
| format | Article |
| id | doaj.art-abdae9b353be40bca6a4114a6fd00c34 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T10:43:11Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-abdae9b353be40bca6a4114a6fd00c342023-11-21T22:49:41ZengMDPI AGVaccines2076-393X2021-06-019659810.3390/vaccines9060598The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United KingdomMichele A. Kohli0Michael Maschio1Joaquin F. Mould-Quevedo2Mansoor Ashraf3Michael F. Drummond4Milton C. Weinstein5Quadrant Health Economics Inc., 92 Cottonwood Crescent, Cambridge, ON N1T 2J1 CanadaQuadrant Health Economics Inc., 92 Cottonwood Crescent, Cambridge, ON N1T 2J1 CanadaSeqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USASeqirus UK, 29 Market St., Maidenhead SL6 8AD, UKCentre for Health Economics, University of York, Heslington, York YO10 5DD, UKHarvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USABackground: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves. Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94. Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (−682,000), hospitalizations (−5800) and deaths (−740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving. Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.https://www.mdpi.com/2076-393X/9/6/598influenza vaccinecost-effectivenesseconomic modeling |
| spellingShingle | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Mansoor Ashraf Michael F. Drummond Milton C. Weinstein The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom Vaccines influenza vaccine cost-effectiveness economic modeling |
| title | The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom |
| title_full | The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom |
| title_fullStr | The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom |
| title_full_unstemmed | The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom |
| title_short | The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom |
| title_sort | cost effectiveness of expanding vaccination with a cell based influenza vaccine to low risk adults aged 50 to 64 years in the united kingdom |
| topic | influenza vaccine cost-effectiveness economic modeling |
| url | https://www.mdpi.com/2076-393X/9/6/598 |
| work_keys_str_mv | AT micheleakohli thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT michaelmaschio thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT joaquinfmouldquevedo thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT mansoorashraf thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT michaelfdrummond thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT miltoncweinstein thecosteffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT micheleakohli costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT michaelmaschio costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT joaquinfmouldquevedo costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT mansoorashraf costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT michaelfdrummond costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom AT miltoncweinstein costeffectivenessofexpandingvaccinationwithacellbasedinfluenzavaccinetolowriskadultsaged50to64yearsintheunitedkingdom |